help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ren, Y.
Right arrow Articles by Mori, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ren, Y.
Right arrow Articles by Mori, M.
Endocrinology Vol. 139, No. 1 195-203
Copyright © 1998 by The Endocrine Society


ARTICLES

Stimulation of the Preprothyrotropin-Releasing Hormone Gene by Epidermal Growth Factor

Ying Ren, Teturou Satoh, Masanobu Yamada, Koshi Hashimoto, Shuntaro Konaka, Toshiharu Iwasaki and Masatomo Mori

First Department of Internal Medicine, Gunma University School of Medicine, Maebashi 371, Japan

Address all correspondence and requests for reprints to: Teturou Satoh, M.D., Ph.D., First Department of Internal Medicine, Gunma University School of Medicine, 3–39-15 Showa-machi, Maebashi 371, Japan.


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Regulation of the expression of the prepro-TRH (ppTRH) gene by epidermal growth factor (EGF) was investigated. The ip injection of EGF significantly stimulated hypothalamic ppTRH messenger RNA levels in rats. To clarify whether this stimulatory effect of EGF could be exerted at the level of gene transcription, the 5'-flanking region (-1893/+127) of the mouse ppTRH gene fused to a luciferase reporter gene was transiently transfected into pituitary GH4C1 cells, and the effect of EGF on gene transcription was measured by a luciferase assay. EGF stimulated ppTRH gene promoter activity in a time- and dose-dependent manner. Deletion analysis revealed that two different regions of the promoter, between -254 and -218 [EGF response element-1 (EGFRE1)] and between -130 and -84 (EGFRE2) were required for full stimulation by EGF. The two EGFREs possessed putative binding sequences for the transcription factor Sp1, and they functioned cooperatively in heterologous promoters. Nuclear extracts from GH4C1 cells specifically bound those two EGFREs in gel retardation assays. Two protein-DNA complexes were found on EGFRE1, whereas four complexes were observed on EGFRE2. Although the binding of nuclear extracts to EGFRE1 was competed for by the consensus Sp1 binding sequence, the complexes on EGFRE1 were not supershifted by an Sp1 antibody. Formation of the slower migrating protein complex on EGFRE1 was prevented by EDTA, suggesting that one of the EGFRE1-binding proteins might be an Sp1-related zinc finger protein. Competition and supershift experiments demonstrated that the EGFRE2-binding protein showing that the slowest migration possessed a characteristic similar to that of Sp1. Selective mutations of the Sp1-binding site in EGFRE2 markedly diminished the EGF-induced stimulation. These results suggest that EGF may function as a positive regulator of ppTRH gene expression, and that the stimulatory effect may be mediated through a cooperative interaction between Sp1 or Sp1-related proteins and additional factors that bind to two separate DNA regions.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
TRH IS A hypothalamic tripeptide that regulates thyroid function by stimulating the synthesis and secretion of TSH in the anterior pituitary gland (1). TRH is derived from a large precursor protein, prepro-TRH (ppTRH), by posttranscriptional processing and enzymatic modification (2). Via a feedback mechanism, expression of the hypothalamic ppTRH gene is negatively regulated by thyroid hormone (3, 4). We recently cloned human and mouse ppTRH genes (5, 6) and characterized the negative response DNA element for thyroid hormone in their promoter regions (6, 7). The levels of hypothalamic ppTRH messenger RNA (mRNA) have been reported to be negatively regulated by glucocorticoid and food deprivation (8, 9). Although the negative regulation of ppTRH gene expression in the hypothalamus has been well studied, as noted above, the factors directly stimulating expression of the hypothalamic ppTRH gene have not been identified.

Epidermal growth factor (EGF), a growth factor initially isolated from the mouse salivary gland (10), is distributed throughout the body and elicits a number of biological responses for cell differentiation and growth (11). In addition, EGF has been reported to stimulate the synthesis and release of several hormones in the pituitary gland. It has been established that EGF stimulates pituitary PRL synthesis at the level of gene transcription through the serum response element of the PRL gene promoter (12, 13). EGF has also been reported to stimulate TSH secretion from perfused rat pituitary glands (14). The iv administration of EGF stimulates TSH release in vivo (14). Fan et al. recently reported that cold stress induced the expression of EGF and its receptor mRNA in pituitary thyrotrophs in rats, suggesting that EGF may have autocrine and/or paracrine roles in the maintenance of the TSH response to cold (15). Although these findings indicated that EGF may modulate thyroid function at the pituitary level by stimulating TSH release in response to some stresses such as cold exposure, the possibility that TSH secretion is augmented by EGF stimulation of the synthesis and secretion of hypothalamic TRH in vivo cannot be ruled out.

It is well known that cold exposure increases the blood level of TSH and thyroid hormone by stimulating the secretion of TRH from the median eminence in the hypothalamus (16). In addition to its stimulatory effect on TRH release, acute and chronic cold exposure elevates the cellular level of TRH mRNA (17, 18). Although several neurotransmitters, such as catecholamines, serotonin, and {gamma}-aminobutyric acid, appear to be involved in the cold exposure-induced TRH release from the median eminence (16), the factors directly stimulating TRH gene expression by cold remain to be determined. Several growth factors, including EGF, have been reported to be synthesized locally in the hypothalamus (19, 20). In response to stress, EGF has been postulated to function as a stimulator of the hypothalamic-pituitary-adrenal axis, and its site of action appears to be at the levels of both the hypothalamus and the pituitary (21, 22). It has been reported that transforming growth factor-{alpha}, a member of the EGF family, stimulates the release of hypothalamic LHRH (23). Taken together, these results prompted us to evaluate the possible regulatory roles of EGF regarding the action of hypothalamic TRH. In the present study we found that EGF stimulated ppTRH gene expression both in vivo and in vitro. Transfection studies using GH4C1 cells revealed that the stimulatory effects may be mediated by direct activation of gene transcription through two separate DNA regions in the TRH gene promoter. We also found that a transcription factor, Sp1, in cooperation with other transcription factors might mediate the stimulatory effect of EGF on mouse TRH gene transcription.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Animal treatment
Male Sprague-Dawley rats, weighing 200 g (n = 6), were housed in light- and temperature-controlled conditions under a 12-h light, 12-h dark cycle, with food and water available ad libitum. Seven days after their arrival, the rats were injected ip with EGF (20 µg/kg BW; Becton Dickinson Labware, Bedford, MA) every 8 h for 3 days. The dose of EGF injected in the rats (10-5 M) was identical to that used in a previous study which stimulated the release of pituitary TSH in vivo (14). Control rats received vehicle isotonic saline injections according to the same schedule. One hour after the final injection of EGF, the rats were killed by decapitation, and the anterior hypothalami were dissected and frozen immediately in liquid nitrogen.

RNA isolation and Northern blot analysis
Total RNA was isolated from individual hypothalami, and Northern blot analysis was performed using a 32P-labeled rat ppTRH complementary RNA probe as described previously (24). The density of the hybridization signals was quantitated by a laser densitometer.

Cell culture
GH4C1, GH3, CV-1, HeLa, and I-10 cells were grown in DMEM supplemented with 10% (vol/vol) FBS, penicillin, streptomycin, and amphotericin B as described previously (6).

Plasmid construction
Plasmids -1893/+127 Luc and -254/+127 Luc were described previously (6), in which -1893/+127 and -254/+127 fragments of the 5'-flanking region of the mouse ppTRH gene, respectively, were ligated to a reporter gene, pA3Luc, possessing the firefly luciferase complementary DNA as a reporter (25, 26) (provided by Dr. William M. Wood). DNA fragments containing various lengths of the 5'-flanking region of the mouse ppTRH gene were amplified by PCR using the -1893/+127 fragment in pGEM4Z (Promega, Madison, WI) as a template. All sense primers for PCR were designed from the nucleotide sequence of the mouse ppTRH gene reported by us (6) and contained a HindIII site in the middle of the primers by changing 1 or 2 bp (bp) from the original sequence to facilitate subsequent subcloning. A common antisense primer (PCR2) corresponding to the region between +68 and +91 was used for PCR, which also contained a HindIII site by changing the C residue at +82 to T. All of the PCR-amplified 5'-flanking sequences, therefore, ended at the same position. The amplified DNA fragments were cut by HindIII and subcloned into pGEM4Z, and the nucleotide sequences were verified by the dideoxy chain termination method (27) using Sequenase version 2 (U.S. Biochemical Corp., Cleveland, OH). Sequence-confirmed DNA fragments were subcloned into a unique HindIII site of the pA3Luc, and the orientation of the inserts was confirmed by sequencing.

Oligonucleotides
The nucleotide sequences of the upper strand of oligonucleotides used for the construction of heterologous promoters and the gel mobility shift assays were as follows (lowercase letters indicate HindIII linker sequences, and underlining indicates putative Sp1-binding sites and point mutations introduced); EGF response element-1 (EGFRE1), 5'-agcTTCCCGGGACGGTCTCTCTCCCTCCCTTTGTTCCCTAGTCAGAGTGTa-3'; EGFRE2, 5'-agcttGGTTTCCGGAAAGCGGGCGGGTCCCCCGGCTCTGCC GTCAGCGCCCCTa-3'; consensus Sp1, AGTCGATCGGGGCGGGGCGA-3'; mutant Sp1, 5'-AGTCGATCGGTTCGGGGCGA-3'; and palindromic thyroid hor-mone response element (TREPAL), 5'-AGTCATCAGGTCATGA-CCTGCGA-3'.

Heterologous promoters
A heterologous promoter (EGFRE1 and -2-TK-Luc) was constructed by insertion of the SmaI/XhoI fragment (-254 to -37) of the mouse ppTRH gene into pT109Luc, which possesses the minimal promoter of the herpes simplex virus thymidine kinase (TK) gene fused to the luciferase gene (28). EGFRE1-TK- and EGFRE2-TK-Luc were constructed by the insertion of a single copy of synthetic oligonucleotide corresponding to the region from -258 to -213 (EGFRE1) or from -130 to -84 (EGFRE2), respectively, into a unique HindIII site of pT109Luc.

PCR-generated site-directed mutagenesis
Point mutations were introduced into the Sp1-binding site at -117 by sequential PCR steps as described previously (29). Two PCR fragments encompassing the mutation were amplified, using the -1893/+127 fragment as the template by the combination of a sense primer (PCR1; 5'-CAAGCACAGGTGCCACTAGAT-3'; residues -381 to -359) and a mutant antisense primer (5'-CAGAGCCGGGGGACCCGAACGCTT-3'; residues -121 to -97) and by the combination of a mutant sense primer (5'-CGGAAAGCGTTCGGGTCCCCCGGCT-3'; residues -125 to -101) and an antisense primer (PCR2; 5'-GACTCTGCAAAGCTTTCCAAGATG-3'; residues +68 to +91). The mutant sense and antisense primers overlapped one another by 20 bp. The two PCR products of the expected lengths were gel purified, heat denatured, and then annealed to each other. The 3'-ends were extended by a Taq DNA polymerase and amplified using the PCR1 and PCR2 primers. The final PCR product was digested by SmaI and HindIII and subcloned into pGEM4Z. The introduced mutation was confirmed by dideoxy sequencing, and the SmaI/HindIII fragment (-254/+83) was subcloned into the SmaI/HindIII sites of pA3Luc.

Transient transfection and luciferase assay
Transient transfection into GH4C1 cells was performed by a calcium phosphate precipitation method with 3 µg reporter constructs as reported previously (5). Glycerol shock was performed for 2 min, 16 h after transfection. The cells were incubated for an additional 48 h in the presence or absence of EGF (100 nM; Collaborative Biomedical Products, Waltham, MA; culture grade). The luciferase assay was carried out as described previously (5). The protein concentrations were measured by Bradford’s method (30), and the luciferase activities were normalized by protein concentration and expressed as light units per µg protein.

Nuclear extracts
Nuclear extracts from HeLa cells were purchased from Stratagene (La Jolla, CA). Nuclear extracts from GH4C1 cells were prepared according to the method of Andrews et al. (31). In brief, confluent GH4C1 cells in a 100-mm culture dish were rinsed twice with ice-cold PBS and then scraped into 0.75 ml PBS. The cells were spun down; resuspended in 200 µl buffer A containing 10 mM HEPES-KOH (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, and 0.2 mM phenylmethylsulfonylfluoride (Sigma Chemical Co., St. Louis, MO); and allowed to swell on ice for 10 min. After centrifugation, nuclear pellets were resuspended in 50 µl buffer C containing 20 mM HEPES-KOH (pH 7.9), 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, and 0.2 mM phenylmethylsulfonylfluoride. After incubation on ice for 20 min followed by a quick spin, the supernatant was used as the nuclear extract. The protein concentration was determined as described above, using BSA as a standard.

Gel mobility shift assays
The double strand oligonucleotides described above were radiolabeled by fill-in reaction with [{alpha}-32P]deoxy-CTP (New England Nuclear, Boston, MA) and were separated from unincorporated isotopes using Sephadex G-25 columns (Boehringer Mannheim, Mannheim, Germany). Binding reactions were performed with 50,000 cpm purified probes and 1 µg nuclear extract for 20 min under conditions described previously (6). For competition experiments, a 200-fold molar excess of cold oligonucleotides was included unless otherwise indicated. For supershift experiments, either 2 µl of a specific rabbit polyclonal antibody for the human Sp1 that cross-reacts to the rat Sp1 (Santa Cruz Biotechnology, Santa Cruz, CA) or normal rabbit serum (NRS) was incubated for an additional 30 min at room temperature. Gel electrophoresis and autoradiography were performed as previously described (6).


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
EGF injection stimulates the levels of hypothalamic ppTRH mRNA
The chronic EGF treatment increased the rats’ steady state levels of hypothalamic ppTRH mRNA (Fig. 1AGo). The densitometric analysis revealed that EGF significantly stimulated TRH mRNA levels by 2-fold (Fig. 1BGo). Although we did not measure EGF levels in the hypothalamus, EGF has been suggested to be transported to the central nervous system from the peripheral circulation through the choloid plexuses, which constitute the blood-cerebrospinal fluid barrier (32).



View larger version (17K):
[in this window]
[in a new window]
 
Figure 1. Chronic EGF treatment stimulated the steady state level of hypothalamic TRH mRNA in rats. A, Northern blot analysis of the hypothalamic TRH mRNA (1.6 kilobases) using a 32P-labeled rat TRH complementary RNA probe. The position of 18S ribosomal RNA is indicated. RNA loading is shown by ethidium bromide staining of the gel. B, Densitometric analysis of hybridization signals. EGF-treated rats showed significantly higher signals (*, P < 0.05) when analyzed by Student’s t test.

 
EGF stimulates ppTRH gene transcription in a dose- and time-dependent manner in vitro
We recently isolated the mouse ppTRH gene and characterized its 5'-flanking sequence -2 kilobases from the transcription start site (6). Using the 5'-flanking sequence (-1893/+127) fused to the firefly luciferase gene, we examined whether EGF stimulation of TRH gene expression was mediated directly by stimulation of ppTRH gene transcription using transient transfection into GH4C1 cells. We used this cell line because hypothalamic neuronal cell lines expressing the endogenous TRH were not available, and the activity of the transfected ppTRH gene promoter in GH4C1 cells was much higher than that in other cell lines, including GH3 cells, HeLa cells, CV-1 cells, and mouse I-10 cells, which were derived from testicular Leydig cell tumors (data not shown). Moreover, GH4C1 cells are known to express functional EGF receptors (33, 34). After transfection, the cells were exposed to graded doses of EGF, and the luciferase activities were measured after 48 h. As shown in Fig. 2AGo, EGF stimulated TRH gene transcription in a dose-dependent manner. Significant stimulation was observed at 10-10 M EGF. Approximately 4-fold stimulation compared with the control value was observed at 10-9 M, but no additional stimulation was observed at 10-8 M EGF. We next studied the time course of EGF stimulation of TRH gene transcription (Fig. 2BGo). The luciferase activities in EGF-treated and control groups at 6 and 12 h did not differ from those at time zero. TRH gene transcription was significantly stimulated after 24 h until 48 h by the addition of 10-8 M EGF, and it decreased thereafter.



View larger version (14K):
[in this window]
[in a new window]
 
Figure 2. A, Dose-dependent stimulation of the mouse ppTRH gene promoter by EGF. The 5'-flanking region (-1893/+127) of the mouse ppTRH gene fused to the luciferase reporter gene was transfected into GH4C1 cells with increasing concentrations of EGF. Luciferase activities were measured after 48 h and are expressed as light units per µg protein. The data are the mean ± SE of three experiments with triplicate determinants. Statistical analysis was performed using Duncan’s multiple range test. Asterisks indicate a significant difference (P < 0.05) from luciferase activity without EGF. B, The time course of EGF stimulation of the ppTRH gene promoter. After transfection, cells were harvested following 0-, 6-, 12-, 24-, 48-, and 72-h exposures to EGF. Cells without EGF treatment were harvested according to the same schedule. The data are the mean ± SE of triplicate plates. The experiment was performed twice with identical results. The luciferase activities after 24, 48, and 72 h of treatment were significantly higher than those of control groups.

 
EGF response elements in the mouse ppTRH gene are located at two separate regions
To delineate the DNA elements responsive to EGF stimulation in the TRH gene promoter, a series of deletion mutants of the 5'-flanking sequence was constructed and transfected with or without 10-8 M EGF. As shown in Fig. 3Go, EGF stimulated the promoter activity of the longest construct (-1893/+127) by approximately 5-fold. In contrast, no significant stimulation was observed in the herpes simplex virus TK gene promoter. The deletion from -1893 to -255 (-254/+127) did not significantly influence EGF stimulation. In contrast, EGF activation was significantly decreased from 5- to 2-fold by deletion of the sequence between -254 and -218 (-217/+83). The further deletion of fragments between -217 and -178 (-177/+83) and between -177 and -131 (-130/+83) did not affect EGF stimulation. Finally, deletion of the element between -130 and -84 (-83/+83) completely abolished the EGF stimulatory effect. No significant stimulation was observed in the -36/+127 construct. These deletion analyses indicated that the DNA elements mediating EGF stimulation of the mouse ppTRH gene were located at two separate regions, i.e. between -254 and -218 and between -130 and -84. We designated the upstream region EGFRE1 and the downstream region EGFRE2.



View larger version (12K):
[in this window]
[in a new window]
 
Figure 3. Delineation of the EGFRE in the mouse ppTRH gene promoter. Deletion mutants of the 5'-flanking region of the mouse ppTRH gene were transfected, and luciferase activities were measured after 48-h exposure to 10 nM EGF. The data are presented as fold stimulation in the presence of EGF and are the mean ± SE of at least three separate experiments. Statistical analysis was performed using Duncan’s multiple range test. The fold stimulations of the -1893 and -254 constructs were significantly higher (P < 0.05) than those of the -217, -177, and -130 constructs (*). The fold stimulations of the -217, -177, and -130 constructs were significantly higher (P < 0.05) than those of the -83 and -36 constructs (**).

 
Nucleotide sequences of the two EGFREs contain putative Sp1-binding sites
Figure 4Go shows the nucleotide sequences of the two EGF response elements identified by deletion analysis. The nucleotide sequence of EGFRE1 is TC rich, and contains a sequence (TCCCTCCC) homologous to a novel Sp1-binding site identified in the acetylcholine receptor {alpha}3 gene promoter (CCCCTCCC) (35). It also possesses a sequence (GGGACG) similar to the GA box (GGGAGG) found in the glial-specific JC virus early promoter (36) that binds Sp1. In contrast, the EGFRE2 sequence is GC rich and possesses a consensus core hexamer of the Sp1-binding site (GGGCGG) (37).



View larger version (17K):
[in this window]
[in a new window]
 
Figure 4. Nucleotide sequences of the two EGFREs identified by deletion analysis. Putative Sp1-binding sites homologous to known Sp1-binding sites in other genes are underlined.

 
The two EGFREs function cooperatively in a heterologous promoter
To assess whether these two regions function as EGFREs in a heterologous promoter, a DNA fragment including the two EGFREs (EGFRE1 and -2-TK-Luc) or an individual fragment of each response element (EGFRE1- and EGFRE2-TK-Luc) was separately linked to a TK gene promoter. The heterologous promoter activities were normalized by the wild TK promoter activities transfected in parallel. The addition of EGFREs to the TK promoter did not alter the basal promoter activity of TK-Luc (data not shown). As shown in Fig. 5Go, EGF stimulated EGFRE1 and -2-TK-Luc significantly, by 1.8-fold. In contrast, neither EGFRE1-TK-Luc nor EGFRE2-TK-Luc was stimulated by EGF. These results indicated that the two separate EGF response elements in the ppTRH gene promoter may function in a cooperative manner. Moreover, the fold stimulation of the EGFRE1 and -2-TK-Luc by EGF was significantly lower than that of the wild-type promoter, suggesting that the positioning of the two EGFREs relative to the transcription start site affects the magnitude of EGF stimulation.



View larger version (22K):
[in this window]
[in a new window]
 
Figure 5. Effect of EGF on the heterologous reporter genes transfected into GH4C1 cells. A DNA fragment (-254/-36) containing the two EGFREs or single copies of EGFRE1 and EGFRE2 were ligated in front of the TK-Luc. The data are presented as fold stimulation in the presence of EGF, and are the mean ± SE of three transfections with triplicate plates.

 
Transcription factor Sp1 binds to EGFRE2 in vitro
To determine whether the nuclear proteins extracted from GH4C1 cells bind to the two EGFREs, two EGFRE oligonucleotides were individually radiolabeled, incubated with nuclear extracts, and resolved in nondenaturing polyacrylamide gels. A no protein-DNA complex was observed with either probe when mixed with unprogrammed rabbit reticulocyte lysates (Fig. 6AGo, lane 2 in both panels). With the EGFRE1 probe, an intense, fast migrating complex B was observed in addition to a weaker, slowly migrating complex A (lanes 3 and 4 in the left panel). In contrast, with the EGFRE2 probe, one intense DNA-protein complex C, migrating in a position similar to that of complex A on EGFRE1, was observed with three additional faster migrating complexes, D, E, and F (lanes 3 and 4 in the right panel). Complex F was present in a position similar to that of complex B on EGFRE1. No new protein-DNA complexes were observed on either probe with nuclear extracts from EGF-treated GH4C1 cells (lanes 5 and 6 in both panels). DNA-protein complexes identical to those detected with HeLa cells were found with GH4C1 cell nuclear extracts on both probes (data not shown).



View larger version (76K):
[in this window]
[in a new window]
 
Figure 6. Characterization of GH4C1 cell nuclear proteins binding to EGFREs by electrophoretic mobility shift assays. A, Mobility shift assays of two EGFREs with GH4C1 nuclear extracts. The two radiolabeled EGFREs were incubated with unprogrammed rabbit reticulocyte lysates or two different concentrations of nuclear extracts from nontreated or 48-h EGF-treated GH4C1 cells. B, Comparison of nuclear protein binding to EGFRE2 with that to the 10-bp Sp1 consensus sequence. Radiolabeled EGFRE2 or the consensus Sp1 sequence was mixed with GH4C1 nuclear extracts and was separated in parallel. A 200-fold molar excess of unlabeled consensus Sp1-binding sequence, EGFRE1, EGFRE2, or TREPAL was added as the competitor to the reaction mixtures. C, Competition by a mutant Sp1 sequence of binding of nuclear proteins to EGFRE2. Graded amounts (200-, 100-, 50-, and 20-fold molar excesses) of an established mutant Sp1 sequence (mutSp1) were used as a competitor, as were EGFRE2, the consensus Sp1 sequence (Sp1), and TREPAL. D, Supershift experiments using a specific antibody for Sp1. Two microliters of an Sp1 antibody (Sp1Ab) or NRS were added to the reaction mixtures. After a 20-min incubation, samples were resolved by electrophoresis. Arrowheads indicate the supershifted protein-DNA complexes.

 
Because the EGFRE2 sequence contained a consensus sequence for the binding site of transcription factor Sp1, we next compared the pattern of protein binding to the EGFRE2 probe with that to the consensus Sp1-binding site. As shown in Fig. 6BGo, four similar DNA-protein complexes formed on EGFRE2 were detected with the consensus Sp1 site (compare lanes 2 in the two panels). Complexes C, D, E, and F formed on the Sp1 oligonucleotide were diminished by incubation with an excess of cold EGFRE2 (lane 5 in the left panel). Conversely, the formation of these four DNA-complexes on EGFRE2 was completely abolished by incubation with unlabeled Sp1 oligonucleotides (lane 5 in the right panel). Unlabeled Sp1 oligonucleotide more effectively inhibited formation of protein-DNA complexes on EGFRE2 than did cold EGFRE2 itself (Fig. 6CGo). Unlabeled EGFRE1 did not affect the four DNA-protein complexes on the Sp1 probe (lane 4 in the left panel), but slightly reduced the complex formation on the EGFRE2 probe (lane 3 in the right panel). A mutant Sp1 oligonucleotide in which the second and third G residues in the GGGCGG motif were substituted by T residues failed to prevent formation of the four DNA-protein complexes (Fig. 6CGo). Furthermore, a TREPAL oligonucleotide, with no relation to the Sp1-binding site, did not inhibit the formation of these complexes (Fig. 6CGo). These results suggest that the formation of all four complexes on the GGGCGG motif in EGFRE2 was specific.

To assess whether the nuclear protein bound to EGFRE2 was bona fide Sp1, a specific antibody for Sp1 was added to the reaction mixtures. As shown in Fig. 6DGo, an anti-Sp1 antibody, but not NRS, supershifted complex C on the EGFRE2 and Sp1 probes, confirming that the major nuclear protein binding to EGFRE2 was the transcription factor Sp1. In contrast, complexes D, E, and F on both probes were not supershifted by the Sp1 antibody.

Two distinct classes of nuclear proteins bind to EGFRE1
The binding of nuclear proteins to the EGFRE1 probe was also reduced by the consensus Sp1 oligonucleotide in a manner similar to that by cold EGFRE1 itself (Fig. 7Go). However, higher concentrations of unlabeled Sp1 oligonucleotide were required to compete with the binding on the EGFRE1 probe compared with the competition of binding to the EGFRE2 probe (Figs. 6CGo and 7Go). The major protein-DNA complex B on EGFRE1 migrated faster than did complex C on EGFRE2 (Fig. 6AGo), and complex A was retarded in a position similar to that of complex C on EGFRE2 (Fig. 6AGo). The two complexes, A and B, on EGFRE1 were not supershifted by an Sp1 antibody (data not shown). These results imply that the EGFRE1-binding proteins were able to bind to the consensus Sp1 sequence with low affinity and were distinguishable from the authentic Sp1. We next examined whether the EGFRE1-binding proteins were the Sp1-related protein that also possesses zinc finger motifs (38, 39). The zinc finger motif requires zinc as a cofactor and can be eliminated by the chelation of zinc ions by adding EDTA to the binding buffer (40). As shown in Fig. 8AGo, the addition of EDTA at a dose as low as 5 mM diminished the complexes C and E on the EGFRE2 probe. In contrast, complexes D and F on EGFRE2 were not affected, even by 50 mM EDTA. These data suggest that complex C on the EGFRE2 probe has a nature compatible with that of Sp1. Complex A on the EGFRE1 probe was obviously sensitive to ETDA, as were complexes C and E on the EGFRE2 probe (Fig. 8BGo), but the formation of complex B was not prevented by 50 mM EDTA. Addition of increasing concentrations of CaCl2 in the presence of 50 mM EDTA did not restore binding of all EDTA-sensitive protein-DNA complexes (data not shown). These results indicate that two distinctive classes of nuclear proteins could bind to EGFRE1, and that the protein-forming complex A might be an Sp1-related zinc finger protein.



View larger version (51K):
[in this window]
[in a new window]
 
Figure 7. The binding of GH4C1 nuclear proteins to EGFRE1 was competed for by the consensus Sp1 sequence. Radiolabeled EGFRE1 was incubated with GH4C1 nuclear extracts in the presence or absence of increasing amounts (0-, 20-, 50-, 100-, and 200-fold molar excesses) of cold EGFRE1 or Sp1 oligonucleotides.

 


View larger version (64K):
[in this window]
[in a new window]
 
Figure 8. Effect of chelation agent EDTA on the formation of protein-DNA complexes on EGFRE1 and -2. Increasing concentrations (0–50 mM) of EDTA were added to binding reaction mixtures, and they were incubated for 20 min.

 
Mutation of the consensus Sp1 site in EGFRE2 reduces EGF stimulation of the ppTRH gene
To determine whether a mutation of the GC box of EGFRE2 could abolish EGF-induced stimulation of ppTRH gene transcription, we introduced point mutations into the consensus Sp1-binding site in the -254/+83 Luc as employed in the gel shift assay (GGGCGG to GTTCGG). As shown in Fig. 9Go, EGF stimulation was significantly reduced in the mutant -254/+83 Luc to approximately 40% of that in the wild-type promoter. The result further confirmed that the GGGCGG motif in EGFRE2 was necessary for the binding of a nuclear protein such as Sp1 to confer the maximal EGF stimulatory action on the mouse ppTRH gene promoter.



View larger version (12K):
[in this window]
[in a new window]
 
Figure 9. Site-directed mutagenesis of the Sp1 site in EGFRE2 reduced the EGF responsiveness of the mouse ppTRH gene promoter. Point mutations were introduced into the Sp1 sequence in EGFRE2 to prevent the binding of Sp1 (mutant -254/+83 Luc). EGF stimulation of the mutant plasmid was compared with that of the wild -254/+83 Luc. Data are presented as fold stimulation in the presence of EGF and are the mean ± SE of three transfections performed with triplicate plates. The asterisk indicates a significant difference (P < 0.01).

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The present results provide new evidence that the administration of EGF stimulates the level of hypothalamic ppTRH mRNA in rats, and that transcription of the ppTRH gene is directly stimulated by EGF in GH4C1 cells. The deletion analysis revealed that the full EGF stimulation required two cis-acting DNA elements spanning from -254 to -218 (EGFRE1) and from -130 to -83 (EGFRE2). Nuclear proteins from GH4C1 cells specifically bound to the two EGFREs in the electrophoretic mobility shift assay. Competition and immunosupershift experiments in the electrophoretic mobility shift assay established that the transcription factor Sp1 was able to bind to the GGGCGG motif in EGFRE2. The consensus Sp1 oligonucleotide more efficiently inhibited protein-DNA complex formation on the EGFRE2 probe than did the unlabeled EGFRE2 itself. This is perhaps because the nucleotide sequence of the Sp1-binding site in EGFRE2, CGGGCGGGTC, differed in two nucleotides (underlined) from the 10-bp consensus Sp1-binding site, G/TG/AGGC/AGG/TG/AG/AC/T (41). Such differences might influence the binding affinity of Sp1 to the target sequence.

Three additional protein-DNA complexes (complexes D, E, and F) were observed on EGFRE2, as were seen on the 10-bp consensus Sp1 sequence. The formation of multiple complexes between nuclear extracts containing the Sp1 and a consensus Sp1 probe has been reported by several groups (38, 39, 42). However, binding factors other than Sp1 have not been fully characterized. In the present study, the consensus Sp1 sequence inhibited the formation of these three complexes on the EGFRE2 probe. Moreover, mutant Sp1 oligonucleotides failed to inhibit the formation of these complexes, and an Sp1 antibody did not supershift the three complexes. These results indicate that nuclear proteins other than Sp1 can bind to the GGGCGG motif in EGFRE2. As the formation of one of these complexes was sensitive to EDTA, the protein forming complex E may be an Sp1-related protein that bound to the GC box by zinc finger motifs but was different in structure from the authentic Sp1. Alternatively, complex E may represent a partially degraded Sp1-DNA complex that was not recognized by an Sp-1 antibody, as the antibody used in the present study was raised against amino acid residues 436–454 of the human Sp1 protein, and these amino acids were not involved in DNA binding (43).

Homologous sequences to Sp1-binding sites identified in other genes (35, 36) were found in the EGFRE1 sequence. However, our competition and supershift analyses demonstrated that the GH4C1 cell nuclear proteins binding to EGFRE1 were distinct from authentic Sp1. As the formation of two complexes on EGFRE1 was differentially affected by EDTA, it was unlikely that the slower migrating band represented oligomerization of the faster migrating one. It is plausible that two different classes of nuclear proteins in GH4C1 cells, which could bind to the Sp1 sequence with lower affinities, may bind to EGFRE1. The protein forming the slower migrating complex on EGFRE1 might also be an Sp1-related zinc finger protein because of its sensitivity to EDTA.

Our transfection studies with heterologous promoters demonstrated that the two EGFREs did not confer EGF stimulation when an individual element was linked to the TK promoter. No stimulatory effect on heterologous promoter activities by EGF has been reported in the EGFREs of other genes fused to the TK gene promoter (44). However, when the DNA fragment containing both EGFREs of the mouse TRH gene was ligated to the TK promoter, the heterologous promoter was significantly stimulated by EGF. These results suggest that the two EGFREs of the mouse TRH gene may mediate EGF stimulation in a cooperative manner. In contrast, a point mutation introduced into EGFRE2 reduced EGF stimulation by approximately 40%, indicating that EGFRE1 can partially mediate EGF stimulation when positioned properly in a homologous promoter. Taken together, these results suggest that the spatial constraint between the two EGFREs and the transcription start site are important factors in the exertion of full EGF stimulation. The requirement for other DNA-binding proteins in addition to Sp1 for full EGF stimulation of the mouse ppTRH gene might be reinforced by the finding that the TK gene promoter, in which Sp1 plays an important role for basal promoter function (37, 41), was not activated by EGF. A cooperative interaction between EGFRE1- and EGFRE2-binding proteins might be necessary to exert maximal EGF stimulation of the mouse ppTRH gene promoter.

The transcription factor Sp1, initially isolated from HeLa cells, binds to a GC-rich sequence in the promoter region and activates a wide variety of cellular genes as well as many viral genes (37, 40). However, whether Sp1 plays a direct role in any signal transduction pathways remains to be clarified. In this context, there are some reports showing an interaction between Sp1 and other transcription factors for the control of gene expression (45, 46). An interesting result was reported by Merchant et al., who showed that stimulation of the gastrin promoter by EGF in GH4 cells was mediated by Sp1 in conjunction with two additional uncharacterized transcription factors binding to the overlapping half-sites of the GC-rich gastrin EGF response element (47). Taken together with these observations, the present results are interpreted to support the possibility that an interaction between different sets of transcription factors and Sp1 is one of the nuclear pathways for the EGF stimulation of specific genes.

In conclusion, the present results suggest that EGF serves as a possible stimulator of ppTRH gene expression. EGF or related growth factors produced locally or from the systemic circulation might be involved in regulation of the level of hypothalamic TRH mRNA. It is known that TRH can be produced by anterior pituitary cells (48, 49). Because the transfection experiments in this study were performed using a clonal pituitary tumor cell line, it is possible that EGF stimulates ppTRH gene expression in subsets of cell types also in the pituitary gland. Further study is required to elucidate the physiological significance of EGF in the regulation of TRH function in vivo.


    Acknowledgments
 
We thank Dr. William M. Wood (University of Colorado Health Sciences Center, Denver, CO) for providing the pA3Luc plasmid.

Received July 21, 1997.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Jackson IMD 1982 Thyrotropin-releasing hormone. N Engl J Med 306:145–155[Medline]
  2. Lechan RM, Wu P, Jackson IMD, Wolfe H, Cooperman S, Mandel G, Goodman RH 1986 Thyrotropin-releasing hormone precursor: characterization in rat brain. Science 231:159–161[Abstract/Free Full Text]
  3. Segerson TP, Kauer J, Wolfe HC, Mobtaker H, Wu P, Jackson IMD, and Lechan RM 1987 Thyroid hormone regulates TRH biosynthesis in the paraventricular nucleus of the rat hypothalamus. Science 238:78–80[Abstract/Free Full Text]
  4. Koller KJ, Wolff RS, Warden MK, Zoeller RT 1987 Thyroid hormone regulate TRH biosynthesis in the paraventricular nucleus. Proc Natl Acad Sci USA 84:7329–7333[Abstract/Free Full Text]
  5. Yamada M, Radvick S, Wondisford F, Nakayama Y, Weintraub BD, Wilber JF 1991 Cloning and structure of human genomic DNA and hypothalamic cDNA encoding human preprothyrotropin-releasing hormone. Mol Endocrinol 4:551–556[CrossRef][Medline]
  6. Satoh T, Yamada M, Iwasaki T, Mori M 1996 Negative regulation of the gene for the preprothyrotropin-releasing hormone from the mouse by thyroid hormone requires additional factor in conjunction with thyroid hormone receptor. J Biol Chem 271:27919–27926[Abstract/Free Full Text]
  7. Feng P, Li QL, Satoh T, Wilber JF 1994 Ligand (T3) dependent and independent effects of thyroid hormone receptors upon human TRH gene transcription in neuroblastoma cells. Biochem Biophys Res Commun 200:171–177[CrossRef][Medline]
  8. Kakucska I, Qi Y, Lechan RM 1995 Changes in adrenal status affect hypothalamic thyrotropin-releasing hormone gene expression in parallel with corticotropin-releasing hormone. Endocrinology 136:2795–2802[Abstract]
  9. van Haasteren GA, Linkels E, Klootwijk W, van Toor H, Rondeel JM, Themmen AP, de Jong FH, Valentijin K, Vaudry H, Bauer K 1995 Starvation induced changes in the hypothalamic content of prothyrotropin-releasing hormone (proTRH) mRNA and the hypothalamic release of proTRH-derived peptides: role of the adrenal gland. J Endocrinol 145:143–153[Abstract/Free Full Text]
  10. Cohen S 1962 Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the newborn animal. J Biol Chem 237:1555–1562[Free Full Text]
  11. Hernandez-Sotomayor S, Carpenter G 1992 Epidermal growth factor receptor: elements of intracellular communication. J Membr Biol 128:81–89[Medline]
  12. Elsholtz HP, Mangalam HJ, Potter E, Albert VR, Supowit S, Evans RM, Rosenfeld MG 1986 Two different cis-active elements transfer the transcriptional effects of both EGF and phorbol esters. Science 234:1552–1557[Abstract/Free Full Text]
  13. Supowit SC, Potter E, Evans RM, Rosenfeld MG 1984 Polypeptide hormone regulation of gene transcription: specific 5' genomic sequence are required for epidermal growth factor and phorbol ester regulation of prolactin gene expression. Proc Natl Acad Sci USA 81:2975–2979[Abstract/Free Full Text]
  14. Altschuler LR, Parist MN, Cageao LF, Chiocchio SR, Fernandez-Po JA, Zaninovich AA 1993 Epidermal growth factor stimulates thyrotropin secretion in the rat. Neuroendocrinology 57:23–27[Medline]
  15. Fan X, Childs GV 1995 Epidermal growth factor and transforming growth factor-alpha messenger ribonucleic acids and their receptors in the rat anterior pituitary: localization and regulation. Endocrinology 136:2284–2293[Abstract]
  16. Arancibia S, Rage F, Astier H, Tapia-Aranchibia L 1996 Neuroendocrine and autonomous mechanisms underlying thermoregulation in cold environment. Neuroendocrinology 64:257–267[Medline]
  17. Zoeller RT, Kabeer N, Albers HE 1990 Cold exposure elevates cellular level of messenger ribonucleic acid encoding thyrotropin-releasing hormone in paraventricular nucleus despite elevated levels of thyroid hormones. Endocrinology 127:2955–2962[Abstract]
  18. Rage F, Lazaro JB, Benyassi A, Aranchibia S, Tapia-Aranchibia L 1994 Rapid changes in somatostatin and TRH mRNA in whole rat hypothalamus in response to acute cold exposure. J Neuroendocriol 6:19–23
  19. Ma YJ, Berg-von der Emde K, Moholy-Siebert M, Hill DF, Ojeda SR 1994 Region-specific regulation of transforming growth factor {alpha}(TGF) gene expression in astrocytes of the neuroendocrine brain. J Neurosci 14:5644–5651[Abstract]
  20. Ma YJ, Hill DF, Junier M, Costa ME, Felder SE, Ojeda SR 1993 Expression of epidermal growth factor receptor changes in the hypothalamus during the onset of female puberty. Mol Cell Neurosci 5:246–262
  21. Luger A, Calogero AE, Kalogeras K, Gallucci WT, Gold PW, Loriaux DL, Chousos GP 1988 Interaction of epidermal growth factor with the hypothalamic-pituitary-adrenal axis: potential physiologic relevance. J Clin Endocrinol Metab 66:334–337[Abstract]
  22. Fan X, Nagle GT, Collins, TJ, Childs GV 1995 Differential regulation of epidermal growth factor and transforming growth factor-alpha messenger ribonucleic acid in the rat anterior pituitary as well as hypothalamus. Endocrinology 136:873–880[Abstract]
  23. Ma YJ, Berg-von der Emde K, Rage F, Wetsel WC, Ojeda SR 1997 Hypothalamic astrocytes respond to transforming growth factor-{alpha} with the secretion of neuroactive substances that stimulate the release of luteinizing hormone-releasing hormone. Endocrinology 138:19–25[Abstract/Free Full Text]
  24. Feng P, Gu J, Kim UJ, Wilber J F 1993 Identification, localization, and developmental studies of rat preprothyrotropin-releasing hormone mRNA in the testis. Neuropeptides 24:63–39[CrossRef][Medline]
  25. Maxwell IH, Harrison GH, Wood WM, Maxwell F 1989 A DNA cassette containing a trimerized SV40 polyadenylation signal which efficiently blocks spurious plasmid-initiated transcription. Biotechniques 7:276–280[Medline]
  26. Wood WM, Kao MY, Gordon DF, Ridgway EC 1989 Thyroid hormone regulates the mouse thyrotropin ß-subunit gene promoter in transfected primary thyrotropes. J Biol Chem 264:14840–14847[Abstract/Free Full Text]
  27. Sanger F, Nicklen S, Coulson A 1977 DNA sequencing with chain-termination inhibitors. Proc Natl Acad Sci USA 74:5463–5467[Abstract/Free Full Text]
  28. Nordeen SK 1988 Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques 6:702–705
  29. Ausubel, FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K 1994 Current Protocols in Molecular Biology. Greene, New York
  30. Bradford M 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248[CrossRef][Medline]
  31. Andrews NC, Faller DV 1991 A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499[Free Full Text]
  32. Plata-Salaman C 1991 Epidermal growth factor and the nervous system. Peptides 12:653–663[CrossRef][Medline]
  33. Johnson LK, Baxter JD, Vlodavsky I, Gospodarowics D 1980 Epidermal growth factor and expression of specific genes: effects on cultured rat pituitary cells are dissociable from mitogenic response. Proc Natl Acad Sci USA 77:394–398[Abstract/Free Full Text]
  34. Halpern J, Hinkle PM 1983 Binding and internalization of epidermal growth factor by rat pituitary tumor cells. Mol Cell Endocrinol 33:183–187[CrossRef][Medline]
  35. Yang X, Fyodorov D, Deneris ES 1995 Transcriptional analysis of acethylcholine receptor {alpha}3 gene promoter motifs that bind Sp1 and AP2. J Biol Chem 270:8514–8520[Abstract/Free Full Text]
  36. Henson JW 1994 Regulation of the glial-specific JC virus early promoter by the transcription factor Sp1. J Biol Chem 269:1046–1050[Abstract/Free Full Text]
  37. Courey AJ, Tjian R 1992 Mechanism of transcriptional control as revealed by studies human transcription factor Sp1. In: McKnight SL, Yamamoto KR (eds) Transcriptional Regulation. Cold Harbor Laboratory Press, Cold Spring Harbor, pp 743–769
  38. Kingsley C, Winoto A 1992 Cloning of GT box-binding protein: a novel Sp1 multigene family regulating T-cell receptor gene expression. Mol Cell Biol 12:4251–4261[Abstract/Free Full Text]
  39. Hagen G, Muller S, Beat M, Suske G 1992 Cloning by recognition site screening of two novel GT box binding protein: a family of Sp1 related genes. Nucleic Acids Res 20:5519–5525[Abstract/Free Full Text]
  40. Kadonaga JT, Carner, KR, Masiarz, FR, Tjian R 1987 Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 51:1079–1090[CrossRef][Medline]
  41. Kadonaga JT, Jones KA, Tjian R 1986 Promoter-specific activation of RNA polymerase II transcription by Sp1. Trends Biochem Sci 11:20–23
  42. Robidoux S, Gosselin P, Harvey M, Leclerc S, Guerin S 1992 Transcription of the mouse secretory protease inhibitor p12 gene is activated by the developmentally regulated positive transcription factor Sp1. Mol Cell Biol 12:3796–3806[Abstract/Free Full Text]
  43. Kadonaga JT, Courey AJ, Ladika J, Tjian R 1988 Distinct region of Sp1 modulate DNA binding and transcriptional activation. Science 24:1566–1570
  44. Shi H, Teng C 1996 Promoter-specific activation of mouse lactoferrin gene by epidermal growth factor involves two adjacent regulatory element. Mol Endocrinol 10:732–741[Abstract]
  45. Look DC, Pelletier MR, Tidwell RM, Roswit WT, Holtzman MJ 1995 Stat1 depends on transcriptional synergy with Sp1. J Biol Chem 270:30264–30267[Abstract/Free Full Text]
  46. Wu RL, Chen TT, Sun TT 1994 Functional importance of an Sp-1 and an NF{kappa}B-related nuclear protein in a keratinocyte-specific promoter of rabbit K3 keratin gene. J Biol Chem 269:28450–28459[Abstract/Free Full Text]
  47. Merchant JL, Shiotani A, Mortensen ER, Shumaker DK 1995 Epidermal growth factor stimulation of the human gastrin promoter requires Sp1. J Biol Chem 270:6314–6319[Abstract/Free Full Text]
  48. Childs GV, Cole DE, Kubek M, Tobin RB, Wilber JF 1978 Endogenous thyrotropin-releasing hormone in the anterior pituitary: sites of activity as identified by immunocytochemical staining. J Histochem Cytochem 26:901–908[Abstract]
  49. Bruhn TO, Bolduc TG, Maclean DB, Jackson IMD 1991 ProTRH peptides are synthesized and secreted by anterior pituitary cells in long-term culture. Endocrinology 129:556–558[Abstract]



This article has been cited by other articles:


Home page
EndocrinologyHome page
K. Hashimoto, S. Matsumoto, M. Yamada, T. Satoh, and M. Mori
Liver X Receptor-{alpha} Gene Expression Is Positively Regulated by Thyroid Hormone
Endocrinology, October 1, 2007; 148(10): 4667 - 4675.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
K. Hashimoto, M. Yamada, S. Matsumoto, T. Monden, T. Satoh, and M. Mori
Mouse Sterol Response Element Binding Protein-1c Gene Expression Is Negatively Regulated by Thyroid Hormone
Endocrinology, September 1, 2006; 147(9): 4292 - 4302.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
A Blondet, J Gout, P Durand, M Begeot, and D Naville
Expression of the human melanocortin-4 receptor gene is controlled by several members of the Sp transcription factor family
J. Mol. Endocrinol., April 1, 2005; 34(2): 317 - 329.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
P. Joseph-Bravo
Hypophysiotropic Thyrotropin-Releasing Hormone Neurons as Transducers of Energy Homeostasis
Endocrinology, November 1, 2004; 145(11): 4813 - 4815.
[Full Text] [PDF]


Home page
EndocrinologyHome page
G. Wang, A. B. Leiter, E. W. Englander, and G. H. Greeley Jr.
Insulin-Like Growth Factor I Increases Rat Peptide YY Promoter Activity through Sp1 Binding Sites
Endocrinology, February 1, 2004; 145(2): 659 - 666.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
H. Xu, M. Inouye, E. R. Hines, J. F. Collins, and F. K. Ghishan
Transcriptional regulation of the human NaPi-IIb cotransporter by EGF in Caco-2 cells involves c-myb
Am J Physiol Cell Physiol, May 1, 2003; 284(5): C1262 - C1271.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
A. Ozawa, M. Yamada, T. Satoh, T. Monden, K. Hashimoto, H. Kohga, Y. Hashiba, T. Sasaki, and M. Mori
Transcriptional Regulation of the Human PRL-Releasing Peptide (PrRP) Receptor Gene by a Dopamine 2 Receptor Agonist: Cloning and Characterization of the Human PrRP Receptor Gene and Its Promoter Region
Mol. Endocrinol., April 1, 2002; 16(4): 785 - 798.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
T. Ishizuka, T. Satoh, T. Monden, N. Shibusawa, T. Hashida, M. Yamada, and M. Mori
Human Immunodeficiency Virus Type 1 Tat Binding Protein-1 Is a Transcriptional Coactivator Specific for TR
Mol. Endocrinol., August 1, 2001; 15(8): 1329 - 1343.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
H. Xu, J. F. Collins, L. Bai, P. R. Kiela, R. M. Lynch, and F. K. Ghishan
Epidermal growth factor regulation of rat NHE2 gene expression
Am J Physiol Cell Physiol, August 1, 2001; 281(2): C504 - C513.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
H. Xu, J. F. Collins, L. Bai, P. R. Kiela, and F. K. Ghishan
Regulation of the human sodium-phosphate cotransporter NaPi-IIb gene promoter by epidermal growth factor
Am J Physiol Cell Physiol, March 1, 2001; 280(3): C628 - C636.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. Satoh, T. Ishizuka, T. Monden, N. Shibusawa, T. Hashida, M. Kishi, M. Yamada, and M. Mori
Regulation of the Mouse Preprothyrotropin-Releasing Hormone Gene by Retinoic Acid Receptor
Endocrinology, November 1, 1999; 140(11): 5004 - 5013.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles